共 223 条
[21]
Bodei L(2013)Lutetium-labelled peptides for therapy of neuroendocrine tumours Neuroendocrinology 97 347-557
[22]
Kidd M(2017)The efficacy of Onco Targets Ther 10 551-716
[23]
Modlin IM(2003)Lu-labelled peptide receptor radionuclide therapy in patients with neuroendocrine tumours: a meta-analysis ANZ J Surg 73 712-413
[24]
Severi S(2016)The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration Turk J Med Sci 46 409-135
[25]
Drozdov I(2017)Everolimus, lutetium- New Engl J Med 376 125-2012
[26]
Nicolini S(2000) DOTATATE and sunitinib for advanced, unresectable or metastatic neuroendocrine tumours with disease progression: a systematic review and cost-effectiveness analysis JAMA 283 2008-1372
[27]
Kwekkeboom DJ(2010)Neuroendocrine gastroenteropancreatic tumors: ESMO clinical recommendation for diagnosis, treatment and follow-up World J Surg 34 1368-181
[28]
Krenning EP(2003) Lu-Dota-octreotate radionuclide therapy of advanced gastrointestinal neuroendocrine tumors: results from a phase II study Semin Radiat Oncol 13 176-156
[29]
Baum RP(2006)Specific efficacy of peptide receptor radionuclide therapy with Semin Nucl Med 36 147-909
[30]
Paganelli G(2016)Lu-octreotate in advanced neuroendocrine tumours of the small intestine Eur Radiol 26 900-390